JP2013534535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534535A5 JP2013534535A5 JP2013519199A JP2013519199A JP2013534535A5 JP 2013534535 A5 JP2013534535 A5 JP 2013534535A5 JP 2013519199 A JP2013519199 A JP 2013519199A JP 2013519199 A JP2013519199 A JP 2013519199A JP 2013534535 A5 JP2013534535 A5 JP 2013534535A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- disease
- lymphoma
- sclc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000003026 hypopharynx Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 206010061311 nervous system neoplasm Diseases 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000002936 ureteral cell Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36350710P | 2010-07-12 | 2010-07-12 | |
| US61/363,507 | 2010-07-12 | ||
| PCT/IB2011/053092 WO2012007896A1 (en) | 2010-07-12 | 2011-07-11 | Multifunctional antibody conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015248537A Division JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534535A JP2013534535A (ja) | 2013-09-05 |
| JP2013534535A5 true JP2013534535A5 (enExample) | 2014-03-20 |
| JP5913307B2 JP5913307B2 (ja) | 2016-04-27 |
Family
ID=44630490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519199A Active JP5913307B2 (ja) | 2010-07-12 | 2011-07-11 | 多機能性抗体複合体 |
| JP2015248537A Active JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015248537A Active JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8741291B2 (enExample) |
| EP (1) | EP2593142B8 (enExample) |
| JP (2) | JP5913307B2 (enExample) |
| KR (1) | KR20130050966A (enExample) |
| CN (1) | CN103096933A (enExample) |
| AR (1) | AR082205A1 (enExample) |
| AU (1) | AU2011277999A1 (enExample) |
| BR (1) | BR112013000951A2 (enExample) |
| CA (1) | CA2804185C (enExample) |
| CO (1) | CO6670522A2 (enExample) |
| ES (1) | ES2704223T3 (enExample) |
| MX (1) | MX2013000491A (enExample) |
| PE (1) | PE20130643A1 (enExample) |
| PH (1) | PH12013500070A1 (enExample) |
| RU (1) | RU2012157167A (enExample) |
| SG (1) | SG186451A1 (enExample) |
| TW (1) | TWI432213B (enExample) |
| WO (1) | WO2012007896A1 (enExample) |
| ZA (1) | ZA201300161B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012059873A2 (en) | 2010-11-05 | 2012-05-10 | Covx Technologies Ireland, Ltd. | Anti-diabetic compounds |
| MX350954B (es) * | 2011-06-21 | 2017-09-26 | Immunogen Inc | Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos. |
| TWI589592B (zh) | 2011-11-17 | 2017-07-01 | 輝瑞股份有限公司 | 胞毒性肽類以及其抗體藥物共軛體 |
| JP6413127B2 (ja) * | 2012-01-09 | 2018-10-31 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 変異抗体およびそのコンジュゲーション |
| WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体－薬物コンジュゲート |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CA2890571A1 (en) | 2012-11-07 | 2014-05-15 | Kenneth G. Geles | Anti-notch3 antibodies and antibody-drug conjugates |
| HK1214161A1 (zh) | 2012-11-07 | 2016-07-22 | 辉瑞公司 | 抗IL-13受体α2抗体和抗体-药物缀合物 |
| EP2917238A1 (en) | 2012-11-08 | 2015-09-16 | Eleven Biotherapeutics, Inc. | Il-6 antagonists and uses thereof |
| AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| CN105829543B (zh) * | 2013-10-14 | 2021-06-01 | 西纳福克斯股份有限公司 | 糖基改造的抗体、抗体-缀合物及其制备方法 |
| CN105814213B (zh) * | 2013-10-14 | 2021-05-04 | 西纳福克斯股份有限公司 | 经修饰的糖蛋白、蛋白质-缀合物及其制备方法 |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| HRP20190431T1 (hr) | 2014-01-31 | 2019-04-19 | Daiichi Sankyo Company, Limited | Anti-her2 antitijelo-lijek konjugat |
| FI3122757T3 (fi) | 2014-02-28 | 2023-10-10 | Hangzhou Dac Biotech Co Ltd | Varautuneita linkkereitä ja niiden konjugointikäyttötapoja |
| ES2754348T3 (es) | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugado de (anticuerpo anti-HER2)-fármaco |
| CN111228511B (zh) | 2014-04-10 | 2024-06-18 | 第一三共株式会社 | 抗her3抗体-药物偶联物 |
| US11142571B2 (en) | 2014-11-07 | 2021-10-12 | Sesen Bio, Inc. | IL-6 antibodies |
| TWI614264B (zh) * | 2015-05-20 | 2018-02-11 | 免疫功坊股份有限公司 | 含胜肽核的多臂接合物及其應用 |
| MX389687B (es) * | 2015-06-19 | 2025-03-20 | Eisai R&D Man Co Ltd | Inmunoglobulinas conjugadas en cys80. |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| US9623118B2 (en) * | 2015-09-01 | 2017-04-18 | Immunwork Inc. | Multi-arm linker constructs for treating pathological blood clots |
| EP3349795B1 (en) * | 2015-09-17 | 2021-03-17 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| WO2017070654A1 (en) * | 2015-10-23 | 2017-04-27 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| US20220008553A1 (en) * | 2015-11-23 | 2022-01-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof |
| CN107029244B (zh) * | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
| JP2019518017A (ja) | 2016-02-09 | 2019-06-27 | アレクサンダー・クランツ | トレースレス親和性標識を使用したタンパク質の部位選択的官能化 |
| EP3419599A4 (en) | 2016-02-23 | 2019-09-11 | Sesen Bio, Inc. | IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
| EP3572428A4 (en) | 2017-01-17 | 2020-12-30 | Daiichi Sankyo Company, Limited | ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20 |
| WO2018138591A1 (en) | 2017-01-24 | 2018-08-02 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
| TWI855528B (zh) | 2017-05-15 | 2024-09-11 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| JP7248578B2 (ja) | 2017-08-31 | 2023-03-29 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| KR20250084239A (ko) | 2017-08-31 | 2025-06-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
| JP2021502418A (ja) * | 2017-11-04 | 2021-01-28 | アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド | ポリペプチドを修飾するための組成物及び方法 |
| WO2019140216A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
| HRP20240756T1 (hr) | 2018-05-18 | 2024-09-13 | Daiichi Sankyo Co., Ltd. | Anti-muc1-eksatekan antitijelo-lijek konjugat |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| EP3831412A4 (en) | 2018-07-31 | 2022-04-27 | Daiichi Sankyo Company, Limited | TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| JP7448638B2 (ja) * | 2019-08-19 | 2024-03-12 | 沈陽薬科大学 | 抗体の変異体及びその使用 |
| EP4025255A1 (en) | 2019-09-04 | 2022-07-13 | Bolt Biotherapeutics, Inc. | Immunoconjugate synthesis method |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス， インコーポレイテッド | Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート |
| CN118201640A (zh) * | 2021-11-01 | 2024-06-14 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物 |
| EP4508091A1 (en) * | 2022-04-15 | 2025-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| CN117801107A (zh) | 2022-09-30 | 2024-04-02 | 上海迪诺医药科技有限公司 | 苯并氮杂卓衍生物、含其的偶联物及其应用 |
| EP4674840A1 (en) | 2023-02-28 | 2026-01-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Chemical coupling linker and use thereof |
| CN118805740B (zh) * | 2024-08-07 | 2025-12-19 | 中国中医科学院中药研究所 | 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| CA2389250C (en) | 1999-10-08 | 2010-07-20 | The Scripps Research Institute | Antibody catalysis of enantio- and diastereo-selective aldol reactions |
| PA8535501A1 (es) | 2001-01-05 | 2003-07-28 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
| US7217845B2 (en) * | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
| DK1656391T3 (da) | 2003-08-13 | 2011-01-03 | Pfizer Prod Inc | Modificerede humane IGF-1R antistoffer |
| EP1853294A4 (en) | 2005-03-03 | 2010-01-27 | Covx Technologies Ireland Ltd | ANTIANGIOGENIC COMPOUNDS |
| JP4897050B2 (ja) * | 2006-11-10 | 2012-03-14 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管形成化合物 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| AU2008295506A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-IGF-1R antibodies and uses thereof |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
-
2011
- 2011-07-11 JP JP2013519199A patent/JP5913307B2/ja active Active
- 2011-07-11 KR KR1020137003413A patent/KR20130050966A/ko not_active Ceased
- 2011-07-11 BR BR112013000951A patent/BR112013000951A2/pt not_active Application Discontinuation
- 2011-07-11 WO PCT/IB2011/053092 patent/WO2012007896A1/en not_active Ceased
- 2011-07-11 CN CN2011800438472A patent/CN103096933A/zh active Pending
- 2011-07-11 EP EP11745833.1A patent/EP2593142B8/en active Active
- 2011-07-11 AR ARP110102486A patent/AR082205A1/es not_active Application Discontinuation
- 2011-07-11 PE PE2013000052A patent/PE20130643A1/es not_active Application Discontinuation
- 2011-07-11 AU AU2011277999A patent/AU2011277999A1/en not_active Abandoned
- 2011-07-11 RU RU2012157167/10A patent/RU2012157167A/ru not_active Application Discontinuation
- 2011-07-11 MX MX2013000491A patent/MX2013000491A/es unknown
- 2011-07-11 PH PH1/2013/500070A patent/PH12013500070A1/en unknown
- 2011-07-11 SG SG2012094983A patent/SG186451A1/en unknown
- 2011-07-11 ES ES11745833T patent/ES2704223T3/es active Active
- 2011-07-11 CA CA2804185A patent/CA2804185C/en active Active
- 2011-07-12 TW TW100124612A patent/TWI432213B/zh not_active IP Right Cessation
- 2011-11-28 US US13/305,354 patent/US8741291B2/en active Active
-
2013
- 2013-01-07 ZA ZA2013/00161A patent/ZA201300161B/en unknown
- 2013-01-11 CO CO13004943A patent/CO6670522A2/es unknown
-
2015
- 2015-12-21 JP JP2015248537A patent/JP6339995B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haendler et al. | Recent developments in antiandrogens and selective androgen receptor modulators | |
| Spano et al. | Molecular networks that regulate cancer metastasis | |
| Azevedo et al. | Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review | |
| JP2010536719A5 (enExample) | ||
| Song et al. | Development of small molecules targeting the Wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer | |
| JP2010532774A5 (enExample) | ||
| JP2011126896A5 (enExample) | ||
| RU2013134359A (ru) | Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований | |
| JP2010516626A5 (enExample) | ||
| EP2193211A4 (en) | IDENTIFICATION OF NEW WAYS FOR ACTIVE DEVELOPMENT FOR LUNG DRESS | |
| BR112013029212A2 (pt) | anticorpos para o tratamento de câncer expressando claudina-6 | |
| JP2017526662A5 (enExample) | ||
| JP2024506612A5 (enExample) | ||
| JP2014506233A5 (enExample) | ||
| EP2148675A4 (en) | ANTI-CANCER FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| JP2013541586A5 (enExample) | ||
| JP2013528215A5 (enExample) | ||
| JP2017536397A5 (enExample) | ||
| JP2013537228A5 (enExample) | ||
| JP2015506352A5 (enExample) | ||
| JP2014005265A5 (enExample) | ||
| WO2012170804A9 (en) | Treatments for gastrointestinal disorders | |
| CL2008003005A1 (es) | Uso de la etilamina del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-isoxazol-3-carboxilico, una sal, hidrato o solvato del mismo para preparar un medicamento util en el tratamiento de diferentes tipos de cancer. | |
| JP2023515687A5 (enExample) | ||
| MX2021005784A (es) | Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer. |